1
|
Rawal SK, Khanna A, Singh A, Jindal T, Sk R, Kumar B, Taori R, Pratihar SK, Vasudeo V, Saurabh N, Ali M, Malla I, Adhikari K. Robot-Assisted Video Endoscopic Inguinal Lymph Node Dissection for Penile Cancer: An Indian Multicenter Experience. J Endourol 2024. [PMID: 38661519 DOI: 10.1089/end.2023.0719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/26/2024] Open
Abstract
Objective: To report outcomes of multicenter series of penile cancer patients undergoing robot-assisted video endoscopic inguinal lymph node dissection (RA-VEIL). Materials and Methods: In this retrospective analysis from 3 tertiary care centers in India, consecutive intermediate-/high-risk carcinoma penis (CaP) patients with nonpalpable inguinal lymphadenopathy and/or nonbulky (<3 cm) mobile inguinal lymphadenopathy undergoing RA-VEIL were included. Patients with matted/bulky (>3 cm) and fixed lymphadenopathy were excluded. Demographic, clinical, and intraoperative data were recorded. Perioperative complications were graded by the Clavien-Dindo classification (CDC). The International Society of Lymphology (ISL) {0-III} grading was used for the assessment of lymphedema. Incidence and pattern of recurrences were assessed on follow-up. Results: From January 1, 2011, to September 30, 2023, 115 patients (230 groins) underwent bilateral RA-VEIL for CaP. The median age of the cohort was 60 (50-69) years. Clinically palpable (either unilateral or bilateral) inguinal lymphadenopathy was seen in 54 patients (47%). The "per groin" median operative time was 120 (100-140) minutes with median lymph node yield of 12 (9-16). No complications were recorded in 87.8% groins operated, with major complications (CDC 3) seen in 2.6% groins. At a median follow-up of 13.5 months, 13 patients had documented recurrences and there were 10 cancer-related deaths. No port-site recurrences were observed. No/minimal lymphedema (ISL 0/I) was seen in 94% legs. Conclusion: RA-VEIL demonstrates safety and oncologic efficacy in penile cancer patients presenting with clinically nonpalpable and/or nonbulky inguinal lymphadenopathy, with favorable functional outcomes.
Collapse
Affiliation(s)
- Sudhir K Rawal
- Department of Uro-Oncology and Robotic Surgery, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Ashish Khanna
- Department of Uro-Oncology and Robotic Surgery, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Amitabh Singh
- Department of Uro-Oncology and Robotic Surgery, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Tarun Jindal
- Department of Uro-Oncology and Robotic Surgery, Apollo Multispecialty Hospitals, Kolkata, West Bengal, India
| | - Raghunath Sk
- Department of Uro-Oncology and Robotic Surgery, HCG Cancer Hospital, Bengaluru, Karnataka, India
| | - Bhuvan Kumar
- Department of Uro-Oncology and Robotic Surgery, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Ravi Taori
- Department of Uro-Oncology and Robotic Surgery, HCG Cancer Hospital, Bengaluru, Karnataka, India
| | - Sarbartha K Pratihar
- Department of Uro-Oncology and Robotic Surgery, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Vivek Vasudeo
- Department of Uro-Oncology and Robotic Surgery, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Nikhil Saurabh
- Department of Uro-Oncology and Robotic Surgery, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Mujahid Ali
- Department of Uro-Oncology and Robotic Surgery, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Ishan Malla
- Department of Uro-Oncology and Robotic Surgery, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Kinju Adhikari
- Department of Uro-Oncology and Robotic Surgery, HCG Cancer Hospital, Bengaluru, Karnataka, India
| |
Collapse
|
2
|
Chakraborty A, Khanna A, Vasudeo V, Pratihar SK, Singh A, Rawal S. Enzalutamide-Induced Acute Maculopapular Rash in Treatment of Metastatic Prostate Cancer: First Case Report from a Tertiary Cancer Care Center of North India. Indian J Surg Oncol 2023; 14:571-575. [PMID: 37900659 PMCID: PMC10611630 DOI: 10.1007/s13193-023-01719-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Accepted: 02/10/2023] [Indexed: 02/19/2023] Open
Abstract
Enzalutamide is a new potent inhibitor of the signaling pathway for the androgen receptor with a half-life of 5.8 days. It has been on the market for the treatment of metastatic castration-resistant prostate cancer since November 2013. We report a case of acute generalized exanthematous maculopapular rash induced by enzalutamide. In summary, newer androgen receptor blockers have a propensity to cause skin related adverse effects. Most common among these are apalutamide. Enzalumatamide, per se, is a safe drug and has not been associated frequently in causing maculopapular rash. Few cases has been reported. In all these cases, the drug was discontinued and 2nd line therapy was instituted. In this report, Enzalutamide was withheld for 10 days and anti-histaminics was instituted. After a full recovery, Enzalutamide was reinstituted in treatment. A 62-year-old male patient with no significant medical history, was diagnosed in March 2020 with metastatic prostatic adenocarcinoma. Baseline PSA was 456 ng/ml. PSMA PET scan showed evidence of multiple bony metastasis. He was started on Degarelix subcutaneous injection with oral abiraterone initially. PSA level showed initial decreasing trend till September 2021 followed by sudden increase. Intramuscular Injection leuprolide was started and initial responses were good followed by later rise of PSA from January. Tab Xtandi (Enzalutamide) was added to the regimen from 31.1.22. Three days after starting enzalutamide treatment, the patient experienced an acute skin reaction. It is about of the plaques covered with widespread millimetric non-follicular papules. Enzalutamide was stopped after appearance of rashes to avoid further serious adverse effects. Anti-histaminics were started. Complete resolution of skin lesions occurred within 10 days. Tab Enzalutamide was reinstituted on 11th day after stoppage and on complete resolution of skin resolutions. According to the CTCAE 5.0 criteria, these skin rash was graded as grade 2. In view of evidence in literature and clinical improvement after stoppage, the acute drug reaction was attributed to enzalutamide. Uro oncologist can be confronted with adverse skin drug reactions attributable to new therapeutic molecules. The slow resolution of symptoms seems be due to the long half-life of enzalutamide. It should not be withdrawn from therapy owing to these effects. Rather, it should be with stopped for 10-14 days. Basic treatment with anti-histaminics or topical steroids may be enough to warranty the resolution of symptoms, and the drug (Enzalutamide) can be continued thereafter.
Collapse
Affiliation(s)
- Arnab Chakraborty
- Department of Genito Urinary Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
- Department of Surgical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Ashish Khanna
- Department of Genito Urinary Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
- Department of Uro-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Vivek Vasudeo
- Department of Genito Urinary Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
- Department of Uro-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Sarbartha Kumar Pratihar
- Department of Genito Urinary Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
- Department of Uro-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Amitabh Singh
- Department of Genito Urinary Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
- Department of Uro-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Sudhir Rawal
- Department of Genito Urinary Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
- Genitourinary Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| |
Collapse
|
3
|
Pratihar SK, Khanna A, Chakraborty A, Vasudeo V, Saurabh N, Kumar B, Ali M, Singh A, Rawal SK. Cutaneous Radiation-Associated Angiosarcoma After Treatment of Carcinoma Penis: First Report from Tertiary Cancer Centre of North India. Indian J Surg Oncol 2023; 14:556-560. [PMID: 37900658 PMCID: PMC10611641 DOI: 10.1007/s13193-023-01766-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2023] [Accepted: 04/29/2023] [Indexed: 10/31/2023] Open
Abstract
Cutaneous radiation-associated angiosarcoma (cRAA) is a rare and aggressive secondary cutaneous angiosarcoma (cAS) with poor survival. cRAA has been mostly reported in breast carcinoma patients. Owing to its rarity, there is scanty literature available and no treatment guidelines. To the best of our knowledge, this is the first report of cRAA after multimodality treatment of carcinoma penis. A sixty-eight-year-old gentleman, a known case of carcinoma penis, underwent total penectomy with perineal urethrostomy and bilateral radical inguinopelvic lymph node dissection 6 years ago. He received adjuvant radiotherapy to the pelvis and bilateral groin. He presented with a bleeding plaque-like lesion with ulceration over the left lower abdomen (within previous radiation field) which rapidly progressed in size over the past 2 months. On examination, the lesion bled profusely on touch. Contrast MRI was suggestive of lobulated exophytic enhancing cutaneous lesion free from underlying muscle. Wedge biopsy was suggestive of cutaneous angiosarcoma. He underwent wide local excision with local perforator flap reconstruction from the right lower abdomen. Histopathology was suggestive of cutaneous angiosarcoma which showed immunoexpression of CD31, ERG1, cMYC suggestive of cRAA. cRAA is a very aggressive disease with 5-year survival of 15-34%. To the best of our knowledge, this is the first ever reported case of cRAA of lower abdomen after multimodality management of carcinoma penis. It masquerades with other benign and less aggressive radiation-induced skin lesions. cMYC immunoexpression is specific for secondary cAS. Wide local resection with negative margin provides the best outcome.
Collapse
Affiliation(s)
- Sarbartha Kumar Pratihar
- Department of Urooncology and Robotic surgery, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5 Rohini, New Delhi, 110085 India
| | - Ashish Khanna
- Department of Urooncology and Robotic surgery, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5 Rohini, New Delhi, 110085 India
| | - Arnab Chakraborty
- Department of Surgical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5 Rohini, New Delhi, India
| | - Vivek Vasudeo
- Department of Urooncology and Robotic surgery, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5 Rohini, New Delhi, 110085 India
| | - Nikhil Saurabh
- Department of Urooncology and Robotic surgery, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5 Rohini, New Delhi, 110085 India
| | - Bhuwan Kumar
- Department of Urooncology and Robotic surgery, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5 Rohini, New Delhi, 110085 India
| | - Mujahid Ali
- Department of Urooncology and Robotic surgery, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5 Rohini, New Delhi, 110085 India
| | - Amitabh Singh
- Department of Urooncology and Robotic surgery, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5 Rohini, New Delhi, 110085 India
| | - Sudhir Kumar Rawal
- Medical Director and Chief Genitourinary Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5 Rohini, New Delhi, India
| |
Collapse
|
4
|
Vasudeo V, Khanna A, Pratihar SK, Jaipuria J, Chakraborty A, Rawal SK, Singh A. Robot-assisted retroperitoneal lymph node dissection for post-chemotherapy residual mass in testicular cancer: Long-term experience from a tertiary care centre. J Minim Access Surg 2023; 19:288-295. [PMID: 36629220 PMCID: PMC10246628 DOI: 10.4103/jmas.jmas_141_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2022] [Revised: 07/03/2022] [Accepted: 07/09/2022] [Indexed: 12/12/2022] Open
Abstract
Objectives To present our intermediate to long-term oncological and functional outcomes of robot-assisted retroperitoneal lymph node dissection (RA-RPLND) in post-chemotherapy (PC) residual mass in testicular cancers. To the best of our knowledge, this is the largest single-centre experience of RA-RPLND for in such setting. Methods Prospectively maintained database of carcinoma testis patients undergoing RA-RPLND from February 2012 to September 2021 was reviewed. Patient demographics, tumour stage and risk groups and chemotherapy details were recorded. Intraoperative details and post-operative complications were also noted. Pathological outcomes included were lymph node yield and histopathology report. Further, follow-up was done for recurrence and antegrade ejaculation status. Results Total of 37 cases were done for PC residual masses. International germ cell cancer collaborative group good, intermediate and poor risk proportion was 18 (48.6%), 14 (37.8%) and 5 (13.5%), respectively. Bilateral full template dissection, unilateral modified template dissection and residual mass excision was performed in 59.5% (22/37), 35.1% (13/37) and 5.4% (2/37) patients, respectively. The median size of the excised residual mass was 3.45 cm interquartile range (IQR 2-6 cm), with the largest being 9 cm. The median lymph nodal yield was 19. The most common histology was necrosis (n = 24, 65%), followed by teratoma (n = 11, 30%) and viable malignancy (n = 2, 5%). Antegrade ejaculation was reported in 32 patients (86.4%). After a median follow-up of 41 (IQR 14-64) months, only one patient had a recurrence. Conclusions RA-PC-RPLND is thus a safe, feasible and oncologically effective option for selected patients. With increasing experience, larger masses can also be dealt with efficiently.
Collapse
Affiliation(s)
- Vivek Vasudeo
- Department of Uro-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Ashish Khanna
- Department of Uro-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | | | - Jiten Jaipuria
- Department of Uro-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Arnab Chakraborty
- Department of Surgical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Sudhir Kumar Rawal
- Department of Uro-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Amitabh Singh
- Department of Uro-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| |
Collapse
|
5
|
Singh A, Khanna A, Jaipuria J, Gupta S, Pratihar SK, Vasudeo V, Gupta R, Rawal SK. Robotic re-exploration for post-operative in house complications following robotic pelvic uro-oncologic surgery: Initial experience, tips and tricks. J Minim Access Surg 2023; 19:95-100. [PMID: 36124468 PMCID: PMC10034803 DOI: 10.4103/jmas.jmas_1_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Purpose Despite widespread acceptance of robotics in urology, literature on using the minimally invasive approach for management of post robotic surgical complications is limited. Here we describe our experience with tips and tricks for robotic re-exploration of post-operative in house complications following robotic pelvic uro-oncologic surgery. Methods A retrospective query of prospectively maintained database was done for all patients who underwent robotic - radical cystoprostatectomy (RCP, 437 patients) and radical prostatectomy (RP, 649 patients), from Jan 2015 or March 2021. Clinical details were collected for all who underwent a second robotic procedure during the same hospital admission for any complication related to the primary surgery. Results Following RCP, 5 patients were re-explored for intestinal obstruction. Surgery was successfully completed in all with a median console time of 80 minutes. Median time to the passage of flatus and discharge from hospital following relook surgery was 3 and 6 days, respectively. Following RP, 3 patients underwent robotic re-exploration (two for reactionary hemorrhage, one for rectal injury). All three cases were managed with a median console time of 75 minutes. Robotic re-exploration was accomplished without extending the skin incision of the index surgery and we did not find an increased incidence of infectious or wound related complications. Conclusion Robotic re-exploration for select post robotic urologic pelvic oncology surgery complications in the immediate and early post-operative period is feasible in the hands of experienced surgeons. Our experience can help others adopt robotics in such scenarios.
Collapse
Affiliation(s)
- Amitabh Singh
- Department of Uro-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Ashish Khanna
- Department of Uro-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Jiten Jaipuria
- Department of Uro-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Shashikant Gupta
- Department of Uro-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | | | - Vivek Vasudeo
- Department of Uro-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Rahul Gupta
- Department of Surgical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Sudhir Kumar Rawal
- Department of Uro-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| |
Collapse
|
6
|
Arya MC, Singhal A, Vasudeo V, Shyoran Y, Gandhi A, Maan R, Sonwal M. Perineal urethrostomy: A single-stage viable option for complex anterior urethral strictures. Urol Ann 2021; 13:142-149. [PMID: 34194140 PMCID: PMC8210710 DOI: 10.4103/ua.ua_111_20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2020] [Accepted: 01/25/2021] [Indexed: 12/04/2022] Open
Abstract
Introduction: Perineal urethrostomy (PU) is a valid single stage option with maximum success to manage complex anterior urethral strictures. Aims: To evaluate the functional outcome of permanent PU using the Blandy technique in older patients or PU with staged reconstruction in young patients with severely diseased distal urethra. Materials and Methods: This is a retrospective analysis of 124 patients. They underwent Blandy's PU with or without Johanson stage 1. Exclusion criteria included patients with posterior urethral strictures or bladder neck contractures. Results: Mean age of patients was 54 years. Strictures due to catheterisation or instrumentation were most common – 85 (68.54%). Out of 124 patients, 71(57.3%) of them were posted for PU with Johanson stage 1 and 53 for PU only (42.7%) according to patients’ choice. In patients age below 50 years, PU (N=10), PU with Johanson stage 1 (N=40) and Johanson stage 2 (N= 8) patients had mean Qmax of 20.2ml/s (17-24), 20.7ml/s (16-26), 16.375ml/s (14-18) respectively. In patients age> 50 years, PU (N=43), PU with Johanson stage 1 (N=31) and Johanson stage 2 (N= 4) patients had mean Qmax of 16.41ml/s (11-24), 17.25ml/s (11-25) and14.75 ml/s (12-17) respectively.For patients with only PU, 8/53 patients (15.09%) required secondary intervention (stomal dilatation N=6 and TURP N=2) while in PU with Johanson stage 1 patients, 10/71(14.08%) required secondary intervention (Stomal dilatation N=6, 8.45% and TURP N= 4, 5.6%). 112/124 (90.32%) were considered successful. Conclusion: Since most of patients have suffered for years, PU provides results in one stage.
Collapse
Affiliation(s)
- Mukesh Chandra Arya
- Department of Urology, Sardar Patel Medical College, Bikaner, Rajasthan, India
| | - Ankur Singhal
- Department of Urology, Sardar Patel Medical College, Bikaner, Rajasthan, India
| | - Vivek Vasudeo
- Department of Urology, Sardar Patel Medical College, Bikaner, Rajasthan, India
| | - Yogendra Shyoran
- Department of Urology, Sardar Patel Medical College, Bikaner, Rajasthan, India
| | - Ajay Gandhi
- Department of Urology, Sardar Patel Medical College, Bikaner, Rajasthan, India
| | - Rakesh Maan
- Department of Urology, Sardar Patel Medical College, Bikaner, Rajasthan, India
| | - Mahesh Sonwal
- Department of Urology, Sardar Patel Medical College, Bikaner, Rajasthan, India
| |
Collapse
|
7
|
Baid M, Arya M, Tiwari R, Vasudeo V, Singh A. Transcaval ureter: A rare embryological anomaly of inferior vena cava causing obstructive uropathy. Urol Sci 2019. [DOI: 10.4103/uros.uros_71_18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
8
|
Kumar L, Tiwari R, Arya MC, Sandhu A, Vasudeo V, Baid M. A tertiary center experience of fracture penis: Early surgical management with a clinical diagnosis. Urol Sci 2018. [DOI: 10.4103/uros.uros_91_18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|